SCA
CLDX icon

SAC Capital Advisors’s Celldex Therapeutics CLDX Stock Holding History

SAC Capital Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-121,242
Closed -$32.1M – 216
2014
Q1 		$32.1M Sell
121,242
-112,524
-48% -$43.1M 0.17% 165
2013
Q4 		$84.9M Buy
233,766
+134,453
+135% +$51.8M 0.49% 47
2013
Q3 		$52.8M Sell
99,313
-167,354
-63% -$57.4M 0.29% 94
2013
Q2 		$62.4M Buy
+266,667
New +$52.5M 0.34% 75

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SAC Capital Advisors's CLDX Position: Q2 2014 in Review

SAC Capital Advisors sold out of Celldex Therapeutics (CLDX) in Q2 2014, closing a stake of 121,242 shares — an estimated $32.1M sold.

SAC Capital Advisors first reported a position in CLDX in Q2 2013 and held it in 4 quarters. The position peaked at $84.9M in Q4 2013. 135 funds tracked by Wall St. Rank hold CLDX as of Q2 2014.

  • SAC Capital Advisors reported no remaining Celldex Therapeutics position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 121,242 Celldex Therapeutics shares in Q2 2014, an estimated $32.1M.
  • SAC Capital Advisors first reported a position in Celldex Therapeutics in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Celldex Therapeutics position peaked at $84.9M in Q4 2013.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.